GlobalData on MSN16d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
This marks the third indication for an interleukin-5 (IL-5) targeting monoclonal antibody, Nucala, in the region for an IL-5 ...
Future Market Insights4d
Global Nasal Allergy Treatment Market to Reach USD 13.3 Billion by 2033 at a CAGR of 6.7% | Data by Future Market Insights, Inc.
According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...